Published in Lab Law Weekly, January 19th, 2007
Commenting on the approval, Chih-Ming Chen, CEO and chairman of Anchen, said, "We are extremely pleased to receive FDA approval of our generic version of Wellbutrin XL. This approval represents an important milestone in Anchen's development and commitment to offer high quality products for consumers at affordable cost."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly